119 related articles for article (PubMed ID: 21899980)
1. Prevalence of beta-lactam nonsusceptible Gram-negative bacilli and use and interpretation of current susceptibility breakpoints: a survey of infectious disease physicians.
Kallen AJ; Beekmann SE; Limbago B; Lentnek AL; Polgreen PM; Patel J; Srinivasan A
Diagn Microbiol Infect Dis; 2011 Nov; 71(3):316-9. PubMed ID: 21899980
[TBL] [Abstract][Full Text] [Related]
2. Breakpoints for extended-spectrum beta-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations.
MacGowan A
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():166-8. PubMed ID: 18154541
[TBL] [Abstract][Full Text] [Related]
3. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases.
Jones RN; Craig WA; Ambrose PG; Dudley MN; Pottumarthy S
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):235-46. PubMed ID: 16105568
[TBL] [Abstract][Full Text] [Related]
4. Multiresistant Enterobacteriaceae: new threat of an old problem.
Pitout JD
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):657-69. PubMed ID: 18847404
[TBL] [Abstract][Full Text] [Related]
5. Impact of CLSI Breakpoint Changes on Microbiology Laboratories and Antimicrobial Stewardship Programs.
Heil EL; Johnson JK
J Clin Microbiol; 2016 Apr; 54(4):840-4. PubMed ID: 26791363
[TBL] [Abstract][Full Text] [Related]
6. beta-Lactams without a suicide inhibitor.
Giamarellou H
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():194-7. PubMed ID: 18154547
[TBL] [Abstract][Full Text] [Related]
7. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
8. Trends in the frequency of multiple drug-resistant Enterobacteriaceae and their susceptibility to ertapenem, imipenem, and other antimicrobial agents: data from the Study for Monitoring Antimicrobial Resistance Trends 2002 to 2007.
Hoban DJ; Bouchillon SK; Hawser SP; Badal RE
Diagn Microbiol Infect Dis; 2010 Jan; 66(1):78-86. PubMed ID: 19733993
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of extended-spectrum beta-lactamase-producing Enterobacteriaceae and trends in antibiotic consumption in a county of Sweden.
Ostholm-Balkhed A; Tärnberg M; Nilsson M; Johansson AV; Hanberger H; Monstein HJ; Nilsson LE
Scand J Infect Dis; 2010 Dec; 42(11-12):831-8. PubMed ID: 20608768
[TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to nemonoxacin, tigecycline, fosfomycin and other antimicrobial agents.
Hsu MS; Liao CH; Liu CY; Yang CJ; Huang YT; Hsueh PR
Int J Antimicrob Agents; 2011 Mar; 37(3):276-8. PubMed ID: 21269811
[No Abstract] [Full Text] [Related]
11. Extended-spectrum beta-lactamase-producing organisms.
Falagas ME; Karageorgopoulos DE
J Hosp Infect; 2009 Dec; 73(4):345-54. PubMed ID: 19596491
[TBL] [Abstract][Full Text] [Related]
12. [Beta-lactam and aminoglycoside resistant phenotypes in enterobacteria isolated in pediatrics].
Ben Hassen A; Chourou O; Fendri C; Kammoun A; Ben Redjeb S
Bull Soc Pathol Exot; 1991; 84(2):145-53. PubMed ID: 1914045
[TBL] [Abstract][Full Text] [Related]
13. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae--EUCAST and CLSI breakpoints.
Kahlmeter G
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():169-74. PubMed ID: 18154542
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, molecular characterization, and phenotypic confirmation of extended-spectrum beta-lactamases in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca at the Radboud University Nijmegen Medical Centre in The Netherlands.
Sturm PD; Bochum ET; van Mook-Vermulst SV; Handgraaf C; Klaassen T; Melchers WJ
Microb Drug Resist; 2010 Mar; 16(1):55-60. PubMed ID: 20001741
[TBL] [Abstract][Full Text] [Related]
15. Prevalence, patient characteristics and outcomes of a novel piperacillin/tazobactam-resistant, pan-β-lactam-susceptible phenotype in Enterobacteriaceae: implications for selective reporting.
Stainton SM; Thabit AK; Kuti JL; Aslanzadeh J; Nicolau DP
Clin Microbiol Infect; 2017 Aug; 23(8):581-582. PubMed ID: 28254605
[No Abstract] [Full Text] [Related]
16. Prevalence of clinical strains resistant to various beta-lactams in a tertiary care hospital in India.
Datta P; Thakur A; Mishra B; Gupta V
Jpn J Infect Dis; 2004 Aug; 57(4):146-9. PubMed ID: 15329445
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility testing accuracy of a CTX-M-type extended-spectrum beta-lactamase organism-producing population of Enterobacteriaceae: intermethod analysis for 9 beta-lactams.
Pottumarthy S; Yu Y; Sader HS; Jones RN; Chen M
Diagn Microbiol Infect Dis; 2005 Oct; 53(2):131-41. PubMed ID: 15939566
[TBL] [Abstract][Full Text] [Related]
18. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum β-lactamase production in clinical Enterobacteriaceae isolates.
Polsfuss S; Bloemberg GV; Giger J; Meyer V; Hombach M
J Antimicrob Chemother; 2012 Jan; 67(1):159-66. PubMed ID: 21972269
[TBL] [Abstract][Full Text] [Related]
19. Plasmid profile of ESBL producing Gram-negative bacteria and correlation with susceptibility to beta-lactam drugs.
Sharma J; Ray P; Sharma M
Indian J Pathol Microbiol; 2010; 53(1):83-6. PubMed ID: 20090229
[TBL] [Abstract][Full Text] [Related]
20. [Detection of resistance phenotypes in gram-negative bacteria].
Navarro F; Calvo J; Cantón R; Fernández-Cuenca F; Mirelis B
Enferm Infecc Microbiol Clin; 2011; 29(7):524-34. PubMed ID: 21696863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
